title: Lung transplantation: a decade of experience.
abstract: BACKGROUND
  Over the past 3 decades, the field of lung transplantation has been refined. However, many barriers exist that limit long-term success. The purpose of this study was to review a single institution's long-term experience with single and double lung transplantation and to assess the effect of different immunosuppressive therapies on outcomes.
  
  
  METHODS
  Lung transplant recipients, both single and double, were reviewed, retrospectively. Patients were divided into five groups: group I, all lung transplants (n = 127); group II, single lung transplants (n = 73); group III, double lung transplants (n = 54); group IV, OKT3 induction therapy recipients (n = 27); and group V, RATG induction therapy recipients (n = 100). Rates of survival, rejection, bronchiolitis obliterans syndrome (BOS) and infection were analyzed at 1, 3, and 5 years.
  
  
  RESULTS
  There were no significant differences in survival, acute rejection rate, freedom from BOS, nor infection between single and double lung transplant recipients. Induction therapy with RATG (group V) was associated with significantly improved survival and freedom from acute rejection, BOS, and infection when compared to OKT3 induction therapy (group IV).
  
  
  CONCLUSIONS
  An earlier impression that RATG is superior to OKT3 induction therapy has borne true in terms of overall survival and incidence of BOS, acute rejection and infection rates. Lung transplantation, using RATG induction therapy, remains an important modality for end-stage pulmonary disease.
authors.affiliation: Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA.
authors.forename: Susan D
authors.initials: SD
authors.lastname: Moffatt
authors.forename: Philippe
authors.initials: P
authors.lastname: Demers
authors.forename: Robert C
authors.initials: RC
authors.lastname: Robbins
authors.forename: Ramona
authors.initials: R
authors.lastname: Doyle
authors.forename: Ann
authors.initials: A
authors.lastname: Wienacker
authors.forename: Noreen
authors.initials: N
authors.lastname: Henig
authors.forename: James
authors.initials: J
authors.lastname: Theodore
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Reitz
authors.forename: Richard I
authors.initials: RI
authors.lastname: Whyte
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001989:Bronchiolitis Obliterans / Q000453:epidemiology / Q000209:etiology; D003550:Cystic Fibrosis / Q000453:epidemiology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016040:Lung Transplantation; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D029424:Pulmonary Disease, Chronic Obstructive / Q000453:epidemiology / Q000628:therapy; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3